The Association of the British Pharmaceutical Industry (ABPI) has suspended Novo Nordisk’s membership for two years due to serious breaches of the ABPI Code of Practice. The suspension stems from a 2021 complaint about a Novo Nordisk-sponsored course advertised in a LinkedIn post. “The action has been taken by the ABPI Board following an extensive investigation and appeals p... Read More